Advertisement
Screener

NEXENTIS TECHNOLOGIES INC. (NXTS) Provision for Loan and Lease Losses

1.6 / 5 stars · 17/54 Roast Me

NEXENTIS TECHNOLOGIES INC. Provision for Loan and Lease Losses

NEXENTIS TECHNOLOGIES INC. (NXTS) reported Provision for Loan and Lease Losses of $116.46 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.

Discontinued › Notes

us-gaap:ProvisionForLoanAndLeaseLosses · last filed 2022-03-31

  • NEXENTIS TECHNOLOGIES INC. provision for loan and lease losses for the quarter ending 2021-12-31 was $362.00, a 98.94% decline year-over-year.
  • NEXENTIS TECHNOLOGIES INC. provision for loan and lease losses for the quarter ending 2021-09-30 was $128.00, a 132.73% increase year-over-year.
  • NEXENTIS TECHNOLOGIES INC. provision for loan and lease losses for the quarter ending 2021-06-30 was -$135.42K, a 208.69% decline year-over-year.
  • NEXENTIS TECHNOLOGIES INC. provision for loan and lease losses for the quarter ending 2021-03-31 was $251.40K, a 1351.06% increase year-over-year.
  • NEXENTIS TECHNOLOGIES INC. provision for loan and lease losses for fiscal 2021 was $116.46K, a 33.91% decline from fiscal 2020.
  • NEXENTIS TECHNOLOGIES INC. provision for loan and lease losses for fiscal 2020 was $176.22K, a 2766.70% increase from fiscal 2019.
  • NEXENTIS TECHNOLOGIES INC. provision for loan and lease losses for fiscal 2019 was $6.15K.
  • NEXENTIS TECHNOLOGIES INC. provision for loan and lease losses for fiscal 2018 was -$54.83K.
Period endProvision for Loan and Lease Losses 3 monthProvision for Loan and Lease Losses 6 monthProvision for Loan and Lease Losses 9 monthProvision for Loan and Lease Losses 12 month
2021-12-31$362.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$490.00
derived: sum of 2 quarters · filed 2022-03-31
-$134.93K
derived: sum of 3 quarters · filed 2022-03-31
$116.46K
10-K · filed 2022-03-31
2021-09-30$128.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
-$135.30K
derived: sum of 2 quarters · filed 2021-11-15
$116.10K
10-Q · filed 2021-11-15
$150.34K
derived: sum of 4 quarters · filed 2022-03-31
2021-06-30-$135.42K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
$115.97K
10-Q · filed 2021-08-16
$150.21K
derived: sum of 3 quarters · filed 2022-03-31
$150.26K
derived: sum of 4 quarters · filed 2022-03-31
2021-03-31$251.40K
10-Q · filed 2021-05-18
$285.63K
derived: sum of 2 quarters · filed 2022-03-31
$285.69K
derived: sum of 3 quarters · filed 2022-03-31
$410.29K
derived: sum of 4 quarters · filed 2022-03-31
2020-12-31$34.23K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$34.29K
derived: sum of 2 quarters · filed 2022-03-31
$158.89K
derived: sum of 3 quarters · filed 2022-03-31
$176.22K
10-K · filed 2022-03-31
2020-09-30$55.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$124.66K
derived: sum of 2 quarters · filed 2021-11-15
$141.98K
10-Q · filed 2021-11-15
$146.76K
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$124.60K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
$141.93K
10-Q · filed 2021-08-16
$146.70K
derived: sum of 3 quarters · filed 2021-08-16
$146.73K
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31$17.32K
10-Q · filed 2021-05-18
$22.10K
derived: sum of 2 quarters · filed 2021-05-18
$22.13K
derived: sum of 3 quarters · filed 2021-05-18
$22.46K
derived: sum of 4 quarters · filed 2021-05-18
2019-12-31$4.78K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
$4.80K
derived: sum of 2 quarters · filed 2021-03-29
$5.14K
derived: sum of 3 quarters · filed 2021-03-29
$6.15K
10-K · filed 2021-03-29
2019-09-30$28.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
$359.00
derived: sum of 2 quarters · filed 2020-11-12
$1.37K
10-Q · filed 2020-11-12
2019-06-30$331.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11
$1.34K
10-Q · filed 2020-08-11
2019-03-31$1.01K
10-Q · filed 2020-05-15
2018-12-31-$54.83K
10-K · filed 2020-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02